Frequently Asked Questions
What is Alachua Government Services and why did it file for bankruptcy?
Alachua Government Services is a biologics contract development and manufacturing organization (CDMO) that specialized in manufacturing vaccines, monoclonal antibodies, recombinant proteins, and nucleic acids for the Department of Defense and other government agencies. The company filed for chapter 11 bankruptcy on July 6, 2025 after government contracts wound down in late 2023 and its parent company, National Resilience, announced it would close 6 of 10 manufacturing plants. Unable to replace government revenue with commercial business, and with the parent unwilling to continue funding operations, the company pursued a 363 sale.
What happened to National Resilience, the parent company?
National Resilience launched in November 2020 with $800 million from Arch Venture Partners and raised over $2 billion in venture capital with the goal of becoming the "world's most advanced biopharmaceutical manufacturing ecosystem." However, the company acknowledged that its capacity expansion outpaced industry demand. In June 2025, Resilience announced it would close 6 of 10 manufacturing plants and added $250 million in bridge financing to support its restructuring. The company continues to operate facilities in Toronto, Philadelphia, Research Triangle Park (NC), and Cincinnati.
What assets were sold in the bankruptcy?
The primary sale involved the debtor's real property in Alachua, Florida: the 183,000-square-foot ADM Facility (a BSL-3 capable biomanufacturing facility opened in 2017) and the 92,000-square-foot Building G (a BSL-2 drug substance and drug product manufacturing facility with single-use technology). Combined, these facilities represent 275,000+ square feet of biomanufacturing facilities. Strive Specialties, Inc. was the winning bidder after a competitive auction. The debtor's Royalty Assets—revenue from cell lines used by third parties in vaccine development—are being sold through a separate process.
What was the issue with DOD equipment?
Approximately 800 pieces of equipment owned by the Department of Defense and other governmental agencies were located at the Alachua Site. This equipment ownership uncertainty delayed the sale process and prevented the debtor from securing a stalking horse bidder prior to filing. The debtor filed a motion to compel the government to remove its equipment, and a stipulation with the DOD regarding removal was approved by the court on October 10, 2025, allowing the sale to proceed.
What is the DCMA disputed claim?
The Defense Contract Management Agency (DCMA) alleges a claim of approximately $24.3 million plus interest against the debtor related to cost reimbursement contracts. The DOD conducted audits spanning fiscal years 2014 through 2018 and subsequently claimed the debtor was overpaid for costs that were unallowable under the Federal Acquisition Regulation. The debtor disputed these claims and had filed appeals to the Armed Services Board of Contract Appeals. An adversary proceeding was filed in the bankruptcy case, with the parties entering a tolling stipulation while negotiations continue.
Why did the UCC investigate National Resilience?
The Official Committee of Unsecured Creditors sought Rule 2004 discovery to investigate the debtor's parent company, National Resilience. With $113 million in affiliate claims on the debtor's books and the parent having raised over $2 billion in venture capital, the committee sought to examine the parent company's transactions and decisions related to the debtor. Both the debtor and National Resilience objected to the investigation, but the court authorized the 2004 examination on October 16, 2025.
What government contracts did the company have?
The company accumulated over $1.8 billion in government contracts during its history. The largest was the 10-year, $400+ million DOD contract awarded in 2013 to build and operate the ADM Facility for Medical Countermeasures Advanced Development and Manufacturing. In February 2020, the company received a contract to develop advanced monoclonal antibody therapy against COVID-19. The company also worked with NIH, NCI, and BARDA on various grants and contracts.
What happened to the company's employees?
The debtor implemented workforce reductions in the months before filing. Approximately 125 employees were laid off between January and April 2025. Additional reductions on June 20 and July 1, 2025 affected approximately 67 more employees—over 80% of the remaining workforce. At the time of filing, only about 13 full-time employees and 3 temporary workers remained, focused primarily on managing the wind-down and maintaining facilities until the sale could be completed.
Who provided DIP financing?
JMB Capital Partners Lending, LLC provided third-party DIP financing in the form of a non-amortizing priming, super-priority senior secured term loan facility of up to $17 million. Norton Rose Fulbright US LLP served as counsel to the DIP Lender. The financing funded the case while the debtor had approximately $2.3 million in cash at filing and the parent company did not provide additional funding.
What is the current status of the CDMO industry?
The biologics CDMO market is projected to grow at 13.7% CAGR through 2029, but experienced a decline in demand from small and emerging biopharma companies in 2023-2024, particularly for initial phases of development. Industry analysts note that many CDMOs expanded capacity during the pandemic beyond what the market could absorb. Venture capital funding in biopharma rebounded in 2024 with 20%+ year-over-year growth, and M&A activity has increased as the industry consolidates.
Who is the claims agent for Alachua Government Services?
Epiq Corporate Restructuring, LLC serves as the claims and noticing agent. The court-authorized role in this case anchors creditor notices and claims-register administration to the filed retention and noticing record.
Read more chapter 11 case research on the ElevenFlo blog.